Mirati Therapeutics, Inc.
COMBINATION THERAPIES

Last updated:

Abstract:

The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a SHP-2 inhibitor and a KRAS G12C inhibitor of Formula (I), Formula I-A or Formula I-B, pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.

Status:
Application
Type:

Utility

Filling date:

5 Dec 2019

Issue date:

17 Mar 2022